GlassScriptPhysician profile
Aaron D Roberds
NPI 1710306089
$2,451.35
in general payments reported to CMS, 2019-2025
30 companies · $309 in 2025
The $309 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $302 · 2021: $381 · 2022: $448 · 2023: $280 · 2024: $450 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $437.38 | 2021-2025 | Freestyle Libre 3, Cardiomems |
| Pfizer INC. | $385.61 | 2019-2025 | |
| Amgen INC. | $378.74 | 2019-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $151.99 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $141.96 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $115.74 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Merck Sharp & Dohme LLC | $94.70 | 2020-2025 | Gardasil 9, Capvaxive |
| Otsuka America Pharmaceutical, INC. | $77.50 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $75.20 | 2021-2025 | Mounjaro, Zepbound |
| Allergan, INC. | $72.49 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.87 | 2019-2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $54.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.81 | 2023-2024 | Jardiance |
| Dexcom, INC. | $33.39 | 2024-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $30.37 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $28.51 | 2021 | |
| Exact Sciences Corporation | $28.25 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $26.18 | 2021-2022 | |
| Mylan Specialty L.P. | $25.37 | 2024 | Yupelri |
| Genentech USA, INC. | $22.00 | 2019 | |
| Sanofi Pasteur INC. | $20.83 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.55 | 2024 | Voquezna |
| Antares Pharma, INC. | $16.34 | 2025 | Xyosted |
| Avanir Pharmaceuticals, INC. | $15.95 | 2020 | |
| Idorsia Pharmaceuticals US INC | $14.85 | 2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.71 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $13.20 | 2019 | |
| Nevro Corp. | $12.80 | 2023 | Senza |
| Novartis Pharmaceuticals Corporation | $12.40 | 2022 | |
| Esperion Therapeutics, INC. | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Roberds listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.